
Neumora Therapeutics, Inc.
80
Recent developments include leadership changes, clinical pipeline progress, financial results, and operational adjustments.
- Neumora named Joshua Pinto as CEO in August 2026 [N2].
- The company reported a narrowing of its Q2 loss and advancement in its CNS pipeline [N2].
- Positive toxicology data was reported for NMRA-215 with an IND planned for Q4 2026 [N4].
- Neumora ended its Phase 3 KOASTAL study of Navacaprant and laid off 35% of its workforce [N2].
- Encouraging Phase 1b data was reported for NMRA-511 in Alzheimer's disease agitation [N8].
- Johnson & Johnson owns stakes in Neumora Therapeutics among other stocks [N1].
Neumora Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company developing treatments for central nervous system disorders. Its pipeline includes NMRA-215, which has shown positive toxicology results and is preparing for an IND filing, and NMRA-511, which has demonstrated encouraging Phase 1b clinical data in Alzheimer's disease agitation. The company has recently undergone leadership changes with Joshua Pinto appointed as CEO and has made strategic decisions including halting the Phase 3 KOASTAL study of Navacaprant and reducing its workforce. Financially, Neumora maintains a strong liquidity position with over $85 million in cash and equivalents as of Q3 2026, despite reporting a net loss in the same period.
Financial figures (if any) are summarized from the latest available SEC filings and are provided for informational purposes only — not financial advice. Neumora Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on CNS disorders with a pipeline including NMRA-215 and NMRA-511. The company reported positive toxicology data for NMRA-215 with an IND planned for Q4 2026 and encouraging Phase 1b data for NMRA-511 in Alzheimer's disease agitation. Leadership changes include the appointment of Joshua Pinto as CEO. The company ended its Phase 3 KOASTAL study of Navacaprant and reduced workforce by 35%. As of September 30, 2026, Neumora held $85.65 million in cash and equivalents, with a current ratio of 4.08 and reported a net loss of $34.44 million for Q3 2026 [S2][N2][N4][N8][N1].
Neumora has demonstrated progress in its CNS pipeline with positive toxicology data for NMRA-215 and encouraging Phase 1b results for NMRA-511, indicating potential for future clinical development milestones. The appointment of a new CEO may bring strategic focus and operational improvements. The company's strong liquidity position provides financial flexibility to support ongoing research and development activities.
The termination of the Phase 3 KOASTAL study of Navacaprant and subsequent workforce reduction highlight challenges in clinical development and operational execution. The company continues to report net losses and negative earnings per share, reflecting the high costs and risks inherent in clinical-stage biopharmaceutical development. Regulatory and clinical trial risks remain significant, and the company depends on successful advancement of its pipeline and capital availability.
Neumora Therapeutics' moat is primarily based on its specialized focus on CNS disorders and its proprietary clinical-stage pipeline targeting unmet medical needs such as Alzheimer's disease agitation. The company's advancement of novel compounds through clinical trials and its ability to generate positive toxicology and early clinical data contribute to its competitive positioning. However, as a clinical-stage biopharmaceutical company, it faces typical industry risks including clinical trial outcomes, regulatory approvals, and the need for continued capital to fund development.
• Clinical Development Risk: Neumora's success depends on the outcomes of clinical trials for its pipeline candidates, which carry inherent uncertainty and potential for failure.
• Regulatory Approval Risk: The company must obtain regulatory approvals for its drug candidates, which involves complex and uncertain processes.
• Financial Risk: Neumora reports net losses and relies on sufficient liquidity and capital raising to fund ongoing operations and development.
• Operational Risk: Recent workforce reductions and study termination indicate operational challenges that may impact execution and timelines.
Business trends: Advancement of CNS pipeline candidates NMRA-215 and NMRA-511 with clinical and toxicology data releases.
Execution milestones: IND filing planned for NMRA-215 in Q4 2026; leadership transition with new CEO; Phase 3 KOASTAL study termination and workforce reduction.
Key risks: Clinical trial and regulatory uncertainties, financial sustainability, and operational execution challenges.
Very high visibility
Visibility score reflects the breadth and consistency of available disclosure across SEC filings, recent public reporting, and baseline business context (research-only; not investment advice).
- Neumora Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing treatments for central nervous system (CNS) disorders.
- The company has a pipeline including NMRA-215 and NMRA-511 targeting CNS conditions such as Alzheimer's disease agitation.
- Neumora reported positive toxicology data for NMRA-215 and plans to file an IND in Q4 2026 [N4].
- The company ended its Phase 3 KOASTAL study of Navacaprant and laid off 35% of its workforce following the study's termination [N2].
- Joshua Pinto was named CEO as of August 2026 [N2].
- Neumora reported a narrowing of its Q2 loss and advancement in its CNS pipeline [N2].
- The company reported encouraging Phase 1b data for NMRA-511 in Alzheimer's disease agitation [N8].
- Neumora's Q3 2026 financial snapshot shows cash and equivalents of $85.65 million, current assets of $94.75 million, current liabilities of $23.19 million, a current ratio of 4.08, and a cash ratio of 5.52 as of September 30, 2026 [S2].
- Net income for Q3 2026 was a loss of $34.44 million with basic and diluted EPS of -$0.18 per share [S2].
- Johnson & Johnson owns stakes in Neumora Therapeutics among other stocks [N1].
Generated 2026-11-16
- S1 | 2026-03-30 | 10-K
- S2 | 2026-11-16 | 10-Q
- N1 | 2026-08-31 | www.nasdaq.com | Johnson & Johnson Owns Stakes in 15 Stocks. Here's the Best of the Bunch. | https://www.nasdaq.com/articles/johnson-johnson-owns-stakes-15-stocks-heres-best-bunch
- N2 | 2026-08-14 | www.nasdaq.com | Neumora Q2 Loss Narrows, Advances CNS Pipeline; Names Joshua Pinto CEO | https://www.nasdaq.com/articles/neumora-q2-loss-narrows-advances-cns-pipeline-names-joshua-pinto-ceo
- N3 | 2026-07-31 | www.nasdaq.com | Weekly Buzz:CIPLA, VTRS Win FDA Nod; BSX Cuts Jobs; ARGX Snaps Up FBRX; JNJ, GSK Strike Deals | https://www.nasdaq.com/articles/weekly-buzz-cipla-vtrs-win-fda-nod-bsx-cuts-jobs-argx-snaps-fbrx-jnj-gsk-strike-deals
- N4 | 2026-07-28 | www.nasdaq.com | Neumora Reports Positive Toxicology Data For NMRA-215; IND Planned For Q4 '26 | https://www.nasdaq.com/articles/neumora-reports-positive-toxicology-data-nmra-215-ind-planned-q4-26
- N5 | 2026-03-27 | www.nasdaq.com | Pre-Market Earnings Report for March 30, 2026 : SGML, BCAX, NMRA, CBAT, PDSB, PAVM | https://www.nasdaq.com/articles/pre-market-earnings-report-march-30-2026-sgml-bcax-nmra-cbat-pdsb-pavm
- N6 | 2026-01-12 | www.nasdaq.com | Leerink Partners Initiates Coverage of Neumora Therapeutics (NMRA) with Outperform Recommendation | https://www.nasdaq.com/articles/leerink-partners-initiates-coverage-neumora-therapeutics-nmra-outperform-recommendation
- N7 | 2026-01-05 | www.nasdaq.com | NMRA Surges On Clinically Meaningful Results In Phase 1 Alzheimer's Disease Agitation Study | https://www.nasdaq.com/articles/nmra-surges-clinically-meaningful-results-phase-1-alzheimers-disease-agitation-study
- N8 | 2026-01-05 | www.nasdaq.com | Neumora Therapeutics Reports Encouraging Phase 1b Data For NMRA-511 In Alzheimer's Disease Agitation | https://www.nasdaq.com/articles/neumora-therapeutics-reports-encouraging-phase-1b-data-nmra-511-alzheimers-disease
This material is for informational purposes only and does not constitute investment, financial, legal or tax advice, or an offer or solicitation to buy or sell any security. The Valye AI Score is a model-based estimate derived from public information and is subject to change without notice. No representation or warranty, express or implied, is made as to the accuracy, completeness or fairness of the information herein. Past performance is not indicative of future results. Investors should conduct their own research and consult a qualified financial adviser before making any investment decisions.

Generated by Valye SEC Pipeline Engine
.gif)


